Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Biotech Investing
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines Life Science Investing
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs Life Science Investing
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG Biotech Investing
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy Life Science Investing
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause Life Science Investing
PainReform's LayerBio's Drop-Less OcuRing-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies Life Science Investing
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
